Third, recent randomized trials found that in those patients with residual invasive disease after preoperative systemic treatment, adjuvant trastuzumab emtansine in HER2-positive BC treated with trastuzumab-based NAC [13] and capecitabine in triple negative (TN) BC treated with anthracycline-taxane NAC [14] both significantly improved survival. Here, ERBB2 is linked to breast cancer.